What is the typical NAD+ dose?
Research-context NAD+ dose ranges vary widely by administration route — intravenous infusion protocols typically use 250-1000 mg per session, while subcutaneous research protocols use lower per-dose amounts due to lower membrane permeability of the intact dinucleotide. NAD+ precursor research (NR, NMN) operates on different dose scales because the precursors are membrane-permeable.
What the research literature says
The NAD+ dose framework is more context-dependent than the peptide-research compounds in the catalog because NAD+ is a coenzyme rather than a receptor-targeted ligand. Intravenous infusion is the most pharmacologically-direct administration route — the intact dinucleotide does not cross cell membranes efficiently, so plasma elevation via IV is the standard approach for systemic protocols.
NAD+ precursor research operates on a different scale because nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) cross cell membranes and convert to NAD+ inside the cell. The Cantó NR characterisation (PMID 22682224) used dose ranges that translate to mg/kg-equivalent doses in rodent metabolic models. The Yoshino review consolidates the precursor-vs-direct-NAD+ dose-framework distinction (PMID 29249689).
The Yang NNMT-pathway work in cancer-associated fibroblasts (PMID 39067875) extended the NAD+-metabolism framework into oncology contexts where the dose-response considerations differ from metabolic-research applications.
Why this matters in research context
NAD+’s dose framework is fundamentally different from the peptide-research compounds because it operates as a coenzyme rather than a receptor-targeted ligand. Researchers should anchor protocol design to the specific NAD+-metabolism endpoint being studied — for systemic plasma-NAD+ elevation, IV is the standard route; for cellular-NAD+-pool research, NR or NMN precursors are more pharmacologically-direct.
Related compounds
- NAD+ 500mg — the compound covered by this answer
- 5-Amino-1MQ 10mg — NNMT inhibitor affecting NAD+ salvage
Related research questions
References
- Cantó C et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15(6):838-847. [PMID 22682224]
- Yoshino J et al. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab 2018;27(3):513-528. [PMID 29249689]
- Yang M et al. NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer 2024;12(7):e009017. [PMID 39067875]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. NAD+ is sold strictly as a research-grade reagent for laboratory and bench research applications.